Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of 4-aminoquinoline compound

A technology of aminoquinoline and compounds, applied in the field of application of 4-aminoquinoline compounds, can solve the problems of high mortality rate in acute multiple organ failure, glucocorticoids cannot be regarded as ideal, and affect the rate of virus clearance, etc. Achieve the effect of preventing or treating acute immune inflammatory response, reducing local vascular permeability, and reducing pulmonary mucus exudation

Pending Publication Date: 2021-08-31
SHANGAI PHARMA GRP CO LTD
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, for acute exudative inflammation, glucocorticoids are usually used to counteract the exudative inflammatory response of the body. However, glucocorticoids cannot be regarded as an ideal treatment strategy. On the contrary, their immunosuppressive effect may affect the clearance rate of the virus. Acute exudative inflammation and the resulting acute multiple organ failure have a high mortality rate, and the use of large doses of glucocorticoids also has adverse reactions such as severe osteoporosis, which cannot well meet the clinical needs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of 4-aminoquinoline compound
  • Application of 4-aminoquinoline compound
  • Application of 4-aminoquinoline compound

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0090] Embodiment 1 uses hydroxychloroquine to treat LPS-induced acute systemic inflammatory response (SIRS) in mice to improve survival rate

[0091] Using the method of intraperitoneal injection of lipopolysaccharide (Lipopolysaccharide, LPS), the systemic inflammation exudation mouse model was prepared, and the specific method steps were as follows:

[0092] 1. Grouping of mice: 8-12 weeks old female C57 mice (weight about 22-25g), after one week of adaptive feeding, were randomly divided into 5 groups according to the weight of the mice, namely the control group, the model group and the low-middle-high group Dosage Hydroxychloroquine group, 10 rats in each group.

[0093] 2. Preparation of SIRS mouse model by intraperitoneal injection of lipopolysaccharide: after dissolving lipopolysaccharide powder with phosphate buffered saline (PBS), intraperitoneal injection to mice at a ratio of 6 mg / kg (mg / kg) body weight to obtain an inflammatory mouse model , and the control group...

Embodiment 2

[0097] Example 2 Using hydroxychloroquine to treat multiple organ injuries in inflammatory mice can significantly prevent and reduce organ exudative inflammation

[0098] Oral gavage was used to administer medium and high doses of hydroxychloroquine to the mice with inflammation, and the model group and treatment group that were normal, dead, and at the end of the observation period were sacrificed and dissected, and their lungs, kidneys, spleen, For liver and intestinal tissues and organs, observe the specimens in general and then conduct HE staining pathological examination. The specific steps are as follows:

[0099] 1. Grouping of mice: 8-12 week-old female C57 mice (with a body weight of about 22-25g), after being adaptively fed for one week in an SPF animal room, were randomly divided into 5 groups according to the weight of the mice, respectively: Blank control (normal mice) group, inflammation mouse model group, hydroxychloroquine medium-dose, high-dose prophylactic dr...

Embodiment 3

[0105] Example 3 Use of hydroxychloroquine to improve abnormal inflammatory response in inflammatory mice

[0106] 3.1 Administration of hydroxychloroquine was administered to inflammatory mice by intragastric administration, peripheral blood was taken for blood routine blood cell level (including lymphocytes, neutrophils, etc.) detection, and the peripheral blood of mice was determined by Elisa The level of relevant inflammatory factors, the specific steps are as follows:

[0107] 1. Grouping of mice: 8-12 week-old female C57 mice (with a body weight of about 22-25g) were fed adaptively for one week in an SPF animal room, and were randomly divided into 4 groups according to the weight of the mice, respectively: Blank control (normal mice) group, inflammatory mouse model group, inflammatory mouse plus hydroxychloroquine group (medium dose, high dose group), the number of each group is 10.

[0108] 2. Intraperitoneal injection of lipopolysaccharide (LPS): add hydroxychloroquin...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of a 4-aminoquinoline compound in preparation of a medicine for inhibiting exudative inflammation. The invention provides the application of the 4-aminoquinoline compound or a pharmaceutically acceptable salt thereof in preparation of the medicine or a pharmaceutical composition for treating and / or preventing exudative inflammation. The pharmaceutical composition comprises the 4-aminoquinoline compound or the pharmaceutically acceptable salt of the 4-aminoquinoline compound, and one or more pharmaceutically acceptable pharmaceutic adjuvants and / or one or more other active ingredients. The 4-aminoquinoline compound, such as chloroquine and hydroxychloroquine, has a good treatment effect on improvement of swelling of cells and exudation of blood vessels and intercellular fluid in an inflammatory state.

Description

technical field [0001] The present invention relates to the application of a 4-aminoquinoline compound or a pharmaceutically acceptable salt thereof in the preparation of medicine or pharmaceutical composition for treating and / or preventing exudative inflammation. Background technique [0002] Exudation refers to the process in which the fluid and cellular components in blood vessels of local inflamed tissues enter the tissue interstitium, body cavity, mucosal surface, and body surface through the blood vessel wall. In the case of inflammation in the body, it is usually accompanied by fluid exudation. This exudative manifestation also has very different pathological and clinical manifestations in different stages of disease development. [0003] Acute exudative inflammation is common in acute infectious inflammation. For example, patients with acute bacterial and viral infections of the lungs, after being attacked by a large number of microorganisms, often quickly change fr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06A61K31/4706A61K31/496A61P11/00A61P31/04A61P31/16A61P31/14A61P31/10
CPCA61K45/06A61K31/4706A61K31/496A61P11/00A61P31/04A61P31/16A61P31/14A61P31/10A61K2300/00Y02A50/30
Inventor 左敏柯樱牛锐刘妍珺夏广新王雪松杜丽莎
Owner SHANGAI PHARMA GRP CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com